Circulating CD4-positive lymphocyte levels as predictor of response to induction chemotherapy in patients with advanced laryngeal cancer.

Circulating CD4-positive lymphocyte levels as predictor of response to induction chemotherapy in patients with advanced laryngeal cancer.
复制标题

DOI:
10.1002/hed.23263
复制
发表时间:
2014-01
影响因子:
2.9
通讯作者:
Taylor, Jeremy
Taylor, Jeremy
中科院分区:
医学2区
文献类型:
--
作者:
Dewyer, Nicholas A.;Wolf, Gregory T.;Light, Emily;Worden, Francis;Urba, Susan;Eisbruch, Avraham;Bradford, Carol R.;Chepeha, Douglas B.;Prince, Mark E.;Moyer, Jeffrey;Taylor, Jeremy

文献摘要

参考文献

被引文献

相似文献

诱导化疗(ICT)后的肿瘤消退确定了对放化疗有反应的喉癌。患者免疫参数最近与化疗反应相关,并可识别反应患者。我们进行了一项回顾性分析,以确定治疗前循环T淋巴细胞水平是否能预测晚期喉癌患者的ICT反应。治疗前,循环T淋巴细胞亚群与治疗反应和生存相关。结果与来自一项涉及口咽癌患者的相同II期试验的类似数据进行了比较。CD 4+细胞百分比的增加预示着ICT的反应,并表明喉癌患者的生存率提高,但口咽癌患者的生存率没有提高。在联合组患者中,CD 4水平升高可预测ICT的反应。这些发现表明免疫系统在化疗反应和临床结果中的潜在重要性。晚期喉癌和口咽癌患者之间的差异可能反映了HPV-16+口咽癌患者细胞免疫功能的不同。
Tumor regression after induction chemotherapy (ICT) identifies laryngeal cancers that are responsive to chemoradiation. Patient immune parameters have recently been associated with response to chemotherapy and may identify responding patients. A retrospective analysis was performed to determine if pretreatment, circulating T lymphocyte levels, predicted ICT response in patients with advanced laryngeal cancer. Pretreatment, circulating T lymphocyte subpopulations were correlated with response to therapy and survival. Results were compared with similar data from an identical Phase II trial involving patients with oropharyngeal cancer. An increased percentage of CD4+ cells predicted response to ICT and suggested improved survival in patients with laryngeal, but not oropharyngeal, cancer. In the combined group of patients, increased CD4 levels predicted response to ICT. These findings demonstrate the potential importance of the immune system in chemotherapy response and clinical outcome. Differences in findings between patients with advanced laryngeal and oropharyngeal cancer may reflect different cellular immunity function in the patients with HPV-16+ oropharyngeal cancer.
DOI: 10.1200/jco.2005.01.2047
发表时间: 2006-02-01
影响因子: 45.3
作者:
Urba, S;Wolf, G;Taylor, J
通讯作者: Taylor, J
DOI: 10.1200/jco.2006.08.5787
发表时间: 2007-03-01
影响因子: 45.3
作者:
Molling, Johan W.;Langius, Jacqueline A. E.;van den Eertwegh, Alfons J. M.
通讯作者: van den Eertwegh, Alfons J. M.
DOI: 10.1097/00008390-200412000-00009
发表时间: 2004-12-01
期刊: MELANOMA RESEARCH
影响因子: 2.2
作者:
Hernberg, MM;Hahka-Kemppinen , MH;Pyrhönen, SO
通讯作者: Pyrhönen, SO
DOI: 10.1097/00005537-200208000-00006
发表时间: 2002-08-01
期刊: LARYNGOSCOPE
影响因子: 2.6
作者:
Wolf, GT;Bradford, CR;Hogikyan, ND
通讯作者: Hogikyan, ND
DOI: 10.1001/archoto.2010.211
发表时间: 2010-12
影响因子: --
作者:
Wansom, Derrick;Light, Emily;Worden, Frank;Prince, Mark;Urba, Susan;Chepeha, Douglas B.;Cordell, Kitrina;Eisbruch, Avraham;Taylor, Jeremy;D'Silva, Nisha;Moyer, Jeffrey;Bradford, Carol R.;Kurnit, David;Kumar, Bhavna;Carey, Thomas E.;Wolf, Gregory T.
通讯作者: Wolf, Gregory T.